Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pure學術人才庫轉入
  4. Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
 
  • Details
Options

Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC

Journal
New England Journal of Medicine
Date Issued
2025-10-30
Author(s)
GEE-CHEN CHANG  
DOI
10.1056/NEJMoa2503001
URI
https://www.scopus.com/pages/publications/105020620968
https://scholars.csmu.edu.tw/handle/123456789/25728
Abstract
BACKGROUND Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC) was significantly improved with amivantamab–lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported. METHODS We randomly assigned, in a 2:2:1 ratio, participants with previously untreated EGFRmutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab–lazertinib, osimertinib, or lazertinib. Overall survival (assessed in an analysis of the time from randomization to death from any cause) in the amivantamab–lazertinib group as compared with the osimertinib group was a key secondary end point. Additional end points included safety. RESULTS A total of 429 participants each were assigned to receive amivantamab–lazertinib or osimertinib. Over a median follow-up of 37.8 months, amivantamab–lazertinib led to significantly longer overall survival than osimertinib (hazard ratio for death, 0.75; 95% confidence interval, 0.61 to 0.92; P=0.005); 3-year overall survival was 60% and 51%, respectively. At the clinical cutoff date, 38% of participants in the amivantamab–lazertinib group and 28% in the osimertinib group were still receiving the assigned treatment. Adverse events of grade 3 or higher were more common with amivantamab–lazertinib (in 80% of participants) than with osimertinib (in 52%), particularly skin-related events, venous thromboembolism, and infusion-related events; these findings were consistent with the established safety profile of each treatment. No new safety signals were observed with additional follow-up. CONCLUSIONS Amivantamab–lazertinib led to significantly longer overall survival among participants with previously untreated EGFR-mutated advanced NSCLC than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback